40-59 y.o.,ASCVD ≥10%, lowbleeding risk52y.o.womenage 55-64 y.o.60y.o.tobaccousediabetesq15yaspirincommunity-dwelling,postmenopausalwomenq1ymammogramtamoxifenHepatitisBinsufficientevidenceforscreening≥ 140mg/dLq3yq2y< 60y.o.50y.o.dementia1 dose; 2doses (2-6monthsapart) ifimmunocomp40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥ 100mg/dL65y.o.Tyrer-Cuzickmodelhormonetherapy2 doses,2-6monthsapartmultidoseinitial series,then 1 doseat 2-6months≥ 200mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors40-70 y.o.,ASCVD ≥10%, lowbleeding risk40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorq1-2ymammogrambased on lifeexpectancy /health statusdyslipidemiaFractureRiskAssessmentTool≥20%statincardiovasculardiseasecolorectalcancerbreastcancer≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors75y.o.≤q2yraloxifenelungcancer≥ 126mg/dLherpeszosterovariancancerq5y40y.o.depressionhypertension≥5.7%pneumococcalHIV≥6.5%Timedup andgo testGailmodelq1ycervicalcancerPREVENTequationoverweight/ obesity3%anxietyaromataseinhibitorsHepatitisC40-59 y.o.,ASCVD ≥10%, lowbleeding risk52y.o.womenage 55-64 y.o.60y.o.tobaccousediabetesq15yaspirincommunity-dwelling,postmenopausalwomenq1ymammogramtamoxifenHepatitisBinsufficientevidenceforscreening≥ 140mg/dLq3yq2y< 60y.o.50y.o.dementia1 dose; 2doses (2-6monthsapart) ifimmunocomp40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factor≥ 100mg/dL65y.o.Tyrer-Cuzickmodelhormonetherapy2 doses,2-6monthsapartmultidoseinitial series,then 1 doseat 2-6months≥ 200mg/dL40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors40-70 y.o.,ASCVD ≥10%, lowbleeding risk40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorq1-2ymammogrambased on lifeexpectancy /health statusdyslipidemiaFractureRiskAssessmentTool≥20%statincardiovasculardiseasecolorectalcancerbreastcancer≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors75y.o.≤q2yraloxifenelungcancer≥ 126mg/dLherpeszosterovariancancerq5y40y.o.depressionhypertension≥5.7%pneumococcalHIV≥6.5%Timedup andgo testGailmodelq1ycervicalcancerPREVENTequationoverweight/ obesity3%anxietyaromataseinhibitorsHepatitisC

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  2. 52 y.o.
  3. women age 55-64 y.o.
  4. 60 y.o.
  5. tobacco use
  6. diabetes
  7. q15y
  8. aspirin
  9. community-dwelling, postmenopausal women
  10. q1y mammogram
  11. tamoxifen
  12. Hepatitis B
  13. insufficient evidence for screening
  14. ≥ 140 mg/dL
  15. q3y
  16. q2y
  17. < 60 y.o.
  18. 50 y.o.
  19. dementia
  20. 1 dose; 2 doses (2-6 months apart) if immunocomp
  21. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  22. ≥ 100 mg/dL
  23. 65 y.o.
  24. Tyrer-Cuzick model
  25. hormone therapy
  26. 2 doses, 2-6 months apart
  27. multidose initial series, then 1 dose at 2-6 months
  28. ≥ 200 mg/dL
  29. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  30. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  31. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  32. q1-2y mammogram based on life expectancy / health status
  33. dyslipidemia
  34. Fracture Risk Assessment Tool
  35. ≥20%
  36. statin
  37. cardiovascular disease
  38. colorectal cancer
  39. breast cancer
  40. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  41. 75 y.o.
  42. ≤ q2y
  43. raloxifene
  44. lung cancer
  45. ≥ 126 mg/dL
  46. herpes zoster
  47. ovarian cancer
  48. q5y
  49. 40 y.o.
  50. depression
  51. hypertension
  52. ≥ 5.7%
  53. pneumococcal
  54. HIV
  55. ≥ 6.5%
  56. Timed up and go test
  57. Gail model
  58. q1y
  59. cervical cancer
  60. PREVENT equation
  61. overweight / obesity
  62. 3%
  63. anxiety
  64. aromatase inhibitors
  65. Hepatitis C